Antimicrobials
Remdesivir

Remdesivir

N/A
N/A
$

Spectrum of Activity

General Information

For COVID-19 positive patients who are moderately ill requiring supplemental oxygen.

  • Hepatic function tests (ALT, AST, bilirubin, alkaline phosphatase, prothrombin time) should be determined prior to starting, and monitored throughout treatment
  • CrCl should be determined prior to starting, and monitored throughout therapy
  • Increase in liver transaminases
  • Decreases in eGFR
  • Nausea
  • Hyperglycemia
  • Increases in prothrombin time

Less common (less than 2%):

  • Generalized seizure
  • Rash
  • Hypersensitivity reactions

No clinical interaction studies have been performed with remdesivir.

Decrease therapeutic effect of Remdesivir:

  • Hydroxychloroquine
  • Chloroquine

Duration of therapy is 5 days.

IV infusion should occur over 30-120 minutes.

Antimicrobial class: Antiviral, adenosine nucleotide prodrug

Pregnancy category: Unknown - Use only if potential benefit justified potential risk to mother and fetus

Average Serum half life: 1 hour